OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
299170$2160.0057

WSI Co Ltd

PharmaceuticalsVerified

WSI Co Ltd has a market price of 2160.0 KRW and a market cap of 73680487920.0 KRW, with a price-to-book ratio of 1.24 and a price-to-tangible-book ratio of 1.24. The company's enterprise value to EBITDA is 20.76, and its enterprise value to revenue is 1.53. The company's liquidity position is characterized by a current ratio of 3.42 and a debt-to-equity ratio of 0.21, indicating a relatively strong liquidity position. The company's profitability metrics are concerning, with a return on equity of -0.0609 and a return on assets of -0.0418, both significantly below the industry median. The company reported a net loss of -3630174980.0 KRW, despite a gross profit of 15410724000.0 KRW and an operating income of 3805405660.0 KRW. The negative net income suggests operational inefficiencies or significant non-operating expenses. WSI Co Ltd's revenue is primarily derived from the sale of pharmaceuticals and medical devices, with a focus on wholesale and retail operations. The company's geographic exposure is concentrated in South Korea, and there is no indication of significant international revenue diversification. The company's revenue concentration in a single geographic region may expose it to local economic and regulatory risks. The company's growth trajectory is mixed, with a revenue of 51706061280.0 KRW in the latest period. However, the company's free cash flow is negative at -2696819840.0 KRW, and capital expenditures are -1030504380.0 KRW, indicating a need for significant investment to sustain operations. The company's operating cash flow of 3090125810.0 KRW provides some liquidity, but the negative free cash flow suggests that the company is not generating sufficient cash to fund its operations and investments. The company's risk assessment indicates a medium liquidity risk and a low dilution risk. However, the key flag of negative net cash after subtracting total debt highlights a potential liquidity constraint. The company's debt-to-equity ratio of 0.21 is relatively low, but the negative net cash position suggests that the company may need to raise additional capital or manage its debt more effectively. Recent events and filings do not indicate any significant changes in the company's operations or financial position. The company's recent financial performance and risk profile suggest that it is in a period of transition, with a need to address its profitability and liquidity challenges.

30-day price · 299170-445.00 (-18.1%)
Low$1897.00High$2625.00Close$2010.00As of21 May, 00:00 UTC
Profile
CompanyWSI Co Ltd
Ticker299170.KQ
SectorHealthcare
BusinessPharmaceuticals & Medical Research
Industry groupPharmaceuticals & Medical Research
IndustryPharmaceuticals
AI analysis

Business. WSI Co Ltd is a Korea-based company engaged in the wholesale and retail of pharmaceuticals and medical devices, as well as the manufacturing and development of medical robots and medical devices, and the manufacturing, sales, and R&D of pharmaceuticals.

Classification. WSI Co Ltd is classified under the Healthcare economic sector, specifically in the Pharmaceuticals & Medical Research business sector, with a classification confidence of 0.92.

WSI Co Ltd has a market price of 2160.0 KRW and a market cap of 73680487920.0 KRW, with a price-to-book ratio of 1.24 and a price-to-tangible-book ratio of 1.24. The company's enterprise value to EBITDA is 20.76, and its enterprise value to revenue is 1.53. The company's liquidity position is characterized by a current ratio of 3.42 and a debt-to-equity ratio of 0.21, indicating a relatively strong liquidity position. The company's profitability metrics are concerning, with a return on equity of -0.0609 and a return on assets of -0.0418, both significantly below the industry median. The company reported a net loss of -3630174980.0 KRW, despite a gross profit of 15410724000.0 KRW and an operating income of 3805405660.0 KRW. The negative net income suggests operational inefficiencies or significant non-operating expenses. WSI Co Ltd's revenue is primarily derived from the sale of pharmaceuticals and medical devices, with a focus on wholesale and retail operations. The company's geographic exposure is concentrated in South Korea, and there is no indication of significant international revenue diversification. The company's revenue concentration in a single geographic region may expose it to local economic and regulatory risks. The company's growth trajectory is mixed, with a revenue of 51706061280.0 KRW in the latest period. However, the company's free cash flow is negative at -2696819840.0 KRW, and capital expenditures are -1030504380.0 KRW, indicating a need for significant investment to sustain operations. The company's operating cash flow of 3090125810.0 KRW provides some liquidity, but the negative free cash flow suggests that the company is not generating sufficient cash to fund its operations and investments. The company's risk assessment indicates a medium liquidity risk and a low dilution risk. However, the key flag of negative net cash after subtracting total debt highlights a potential liquidity constraint. The company's debt-to-equity ratio of 0.21 is relatively low, but the negative net cash position suggests that the company may need to raise additional capital or manage its debt more effectively. Recent events and filings do not indicate any significant changes in the company's operations or financial position. The company's recent financial performance and risk profile suggest that it is in a period of transition, with a need to address its profitability and liquidity challenges.
Key takeaways
  • WSI Co Ltd is a South Korea-based company with a focus on pharmaceuticals and medical devices, but it is currently reporting a net loss.
  • The company's liquidity position is relatively strong, with a current ratio of 3.42 and a debt-to-equity ratio of 0.21.
  • WSI Co Ltd's profitability metrics are below industry medians, with a return on equity of -0.0609 and a return on assets of -0.0418.
  • The company's revenue is concentrated in South Korea, and it has a negative free cash flow, indicating a need for significant investment.
  • The company's risk assessment indicates a medium liquidity risk and a low dilution risk, but it has a key flag of negative net cash after subtracting total debt.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyKRW
Revenue$51.71B
Gross profit$15.41B
Operating income$3.81B
Net income-$3.63B
R&D
SG&A
D&A
SBC
Operating cash flow$3.09B
CapEx-$1.03B
Free cash flow-$2.70B
Total assets$86.86B
Total liabilities$27.24B
Total equity$59.62B
Cash & equivalents$6.97B
Long-term debt$12.30B
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY0
FY-1
FY-2
FY-3
FY-4
PeriodGross %Op %Net %FCF %
FY0
FY-1
FY-2
FY-3
FY-4
PeriodAssetsEquityCashDebt
FY0
FY-1
FY-2
FY-3
FY-4
PeriodOCFCapExFCFSBC
FY0
FY-1
FY-2
FY-3
FY-4
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodGross %Op %Net %FCF %
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodAssetsEquityCashDebt
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodOCFCapExFCFSBC
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
Valuation
Market price$2160.00
Market cap$73.68B
Enterprise value$79.01B
P/E
Reported non-GAAP P/E
EV/Revenue1.5
EV/Op income20.8
EV/OCF25.6
P/B1.2
P/Tangible book1.2
Tangible book$59.62B
Net cash-$5.33B
Current ratio3.4
Debt/Equity0.2
ROA-4.2%
ROE-6.1%
Cash conversion-85.0%
CapEx/Revenue-2.0%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Pharmaceuticals & Medical Research · cohort 1 companies
Metric299170Activity
Op margin7.4%-2.9% medp25 -218.9% · p75 9.6%above median
Net margin-7.0%28.2% medp25 28.2% · p75 28.2%bottom quartile
Gross margin29.8%47.8% medp25 27.6% · p75 68.9%below median
CapEx / revenue-2.0%6.6% medp25 6.6% · p75 6.6%bottom quartile
Debt / equity21.0%271.5% medp25 271.5% · p75 271.5%bottom quartile
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-10 06:07 UTC#224add85
Market quoteclose KRW 2160.00 · shares 0.03B diluted
no public URL
2026-05-10 06:07 UTC#7254a2e2
Source: analysis-pipeline (hybrid)Generated: 2026-05-10 06:10 UTCJob: d8244f4a